Biotechnology
Commented by André Will-Laudien on May 22nd, 2025 | 07:20 CEST
Caution! Takeover imminent at Evotec or BioNxt, tension remains high at Bayer and Valneva
In advanced stock market cycles, many investors wonder where returns can still be made. Defense and high tech have raced ahead, and a sector rotation remains, particularly in favor of biotech. Despite substantial gains in major indices such as the DAX 40, up nearly 20%, the Nasdaq Biotech Index (NBI) is still down nearly 7%. The excitement is mounting, as some stocks are heading north and delivering better-than-expected figures. From an analytical perspective, Evotec and BioNxt are so undervalued that a takeover can no longer be ruled out. Bayer has issued a strong statement to the US courts, and Valneva is set to outperform its previous year's Q1 figures significantly. Time for an update: Where are the buying opportunities?
Read
Commented by Armin Schulz on May 22nd, 2025 | 07:10 CEST
Overlooked gems? Why artificial intelligence will catapult Novo Nordisk, NetraMark, and UnitedHealth to the forefront
The pharmaceutical industry is undergoing a historic transformation. Artificial intelligence is compressing drug development times from decades to months, reducing costs by billions, and unlocking therapies for previously untreatable diseases. Algorithms sift through genome data, simulate drug candidates, and optimize clinical trials with a precision that surpasses that of human researchers. This disruption is not only creating medical milestones but also lucrative opportunities for investors. Today, we look at three candidates and analyze the current situation at Novo Nordisk, NetraMark Holdings, and UnitedHealth.
Read
Commented by Fabian Lorenz on May 21st, 2025 | 07:00 CEST
Stocks on the verge of MULTIPLYING? BioNTech, D-Wave, and hot stock Argo Living Soils aim to revolutionize their markets! Buy now?
These companies want to turn billion-dollar markets upside down: Argo Living Soils, BioNTech, and D-Wave. Argo Living Soils aims to revolutionize infrastructure construction through nanotechnology. Concrete and asphalt are to become more durable and environmentally friendly through nanotechnology. This could, for example, make buildings and bridges better protected against earthquakes. The potential is enormous, and the hot stock is valued at less than CAD 10 million, offering the chance for a multiple increase. D-Wave has impressively demonstrated how quickly a revaluation can take place. Quantum computing has the potential to change the world. But big players like Alphabet, NVIDIA, and others also want a big piece of the pie. At BioNTech, the focus remains on the fight against cancer. The stock appears to have halted its sell-off, but analysts are lowering their price targets. Where is the right entry point now?
Read
Commented by André Will-Laudien on May 20th, 2025 | 07:10 CEST
Where will the biotech winner of 2025 come from? Evotec, Bayer, BioNTech, Vidac Pharma, and Pfizer under stock review
With new announcements coming out of Washington daily, the stock market carousel is spinning faster and faster. The direction is no longer uniformly upward, but deeper corrections, such as those seen in April, offer good entry opportunities. While the DAX 40 index reached a new all-time high yesterday at 23,977 points and has already recorded 27% growth in 2025, the Nasdaq Biotech Index (NBI) has lost a full 7.2% over the past six months. We have examined several interesting sector players and identified both opportunities and risks. In short, careful selection is once again key!
Read
Commented by Stefan Feulner on May 20th, 2025 | 07:05 CEST
Super Micro, NetraMark, Rigetti – Trump push promises potential
The suspension of tariffs between the two superpowers, the US and China, continues to boost technology and semiconductor stocks such as Nvidia and Super Micro Computer. Tech giant Apple, which initially suffered from the 145% tariffs imposed by US President Donald Trump, is also benefiting enormously from the current deal. AI stocks have also performed well in their wake and are poised for further upward momentum.
Read
Commented by Mario Hose on May 16th, 2025 | 14:00 CEST
Save the date and register now for free: From the raw materials boom to the AI revolution: Leading companies from five continents will present future opportunities on May 21, 2025, at the 15th International Investment Forum (IIF)
If you want to understand the trends of tomorrow, you need to hear directly from the people shaping them today. The 15th International Investment Forum (IIF) gives you that opportunity: On May 21, 2025, CEOs, investors, and thought leaders from across the globe will gather online to share insights from key sectors like industry, defense, mining, cleantech, biotech, AI, and more. In live presentations and interactive discussions, companies such as Germany's CENIT AG, Canada's First Phosphate Corp., dynaCert, Desert Gold, and Australia's Manuka Resources will provide exclusive insights into their strategies. The digital conference will be moderated by Stockhouse media star Lyndsay Malchuk, who is well-known for her incisive interviews. Why should you attend this event?
Read
Commented by Armin Schulz on May 14th, 2025 | 07:00 CEST
Patents, partnerships & tumor strategies: How Novo Nordisk, BioNxt Solutions, and BioNTech are securing tomorrow's profits
The global pharmaceutical industry, once the epitome of stable investments, is undergoing radical change. While protectionist trade barriers are disrupting supply chains and causing stock market prices to plummet, companies are forecasting growth for the biotech and pharmaceutical industries, according to the industry study "Life Sciences Executives Flash Report." The crisis is turning out to be a laboratory of opportunities – those who prioritize digital therapies, mRNA technologies, or sustainable production models now could emerge as winners in a reorganized market. But which strategies are convincing? We take a closer look at Novo Nordisk, BioNxt Solutions, and BioNTech.
Read
Commented by Nico Popp on May 13th, 2025 | 07:10 CEST
The fight against cancer as a billion-dollar opportunity: BioNTech, Merck, and Vidac Pharma
Cancer is the scourge of our time. However, significant progress has already been made in recent years. In addition to significantly improved traditional therapies, individualized treatment approaches such as immunotherapy are repeatedly proving successful in curing patients. This trend is set to continue. Experts such as the investors at Candriam and market researchers at Spherical Insights foresee enormous growth – the market for cancer drugs could see double-digit annual growth by the 2030s. Market leaders such as BioNTech and Merck, as well as insider tips like Vidac Pharma, stand to benefit.
Read
Commented by Fabian Lorenz on May 12th, 2025 | 07:05 CEST
Gold at USD 6,000 and takeover rumors: Evotec, Barrick Gold, and Desert Gold shares
Evotec shares shot up by over 10% on Friday. Is it due to the payment from the Gates Foundation? Or is there a new attempt to buy German biotech companies soon? Desert Gold is a hot takeover candidate in the gold sector. The Canadians aim to expand their resources to 2 million ounces and start production soon. Analysts at GBC Research believe the share price could multiply. GBC's estimates are based on a gold price of USD 2,300. Currently, the precious metal is trading above USD 3,000. According to experts, USD 6,000 is even possible. In that case, even Barrick could strike it rich. However, the latest first-quarter report failed to provide new momentum for the stock. Are acquisitions needed?
Read
Commented by Armin Schulz on May 8th, 2025 | 07:05 CEST
Cancer revolution: How Bayer, Vidac Pharma, and Pfizer are shaking up the billion-dollar market
Oncology has become the scene of an unprecedented competition. Where billion-dollar markets meet life-saving innovations, a global playing field for pioneers is emerging. Forecasts show that therapy costs and market volume are growing exponentially. This poses a challenge for healthcare systems and represents a gold mine for visionaries. New technologies such as personalized cancer vaccines and targeted drugs are pushing the boundaries of what is possible. Three players are strategically positioning themselves in this dynamic environment: Bayer, Vidac Pharma, and Pfizer. Their next moves could shape not only patients' lives, but entire industries.
Read